Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
BMC Infect Dis. 2018 Jan 25;18(1):54. doi: 10.1186/s12879-018-2961-8.
The majority of people living with HIV require antiretroviral therapy (ART) for controlling viral replication, however there are rare HIV controllers who spontaneously and durably control HIV in the absence of treatment. Understanding what mediates viral control in these individuals has provided us with insights into the immune mechanisms that may be important to induce for a vaccine or functional cure for HIV. To date, few African elite controllers from high incidence settings have been described. We identified virological controllers from the CAPRISA 002 cohort of HIV-1 subtype C infected women in KwaZulu Natal, South Africa, two (1%) of whom were elite controllers. We examined the genetic, clinical, immunological and virological characteristics of these two elite HIV controllers in detail, to determine whether they exhibit features of putative viral control similar to those described for elite controllers reported in the literature.
In this case report, we present clinical features, CD4 T cell and viral load trajectories for two African women over 7 years of HIV infection. Viral load became undetectable 10 months after HIV infection in Elite Controller 1 (EC1), and after 6 weeks in Elite Controller 2 (EC2), and remained undetectable for the duration of follow-up, in the absence of ART. Both elite controllers expressed multiple HLA Class I and II haplotypes previously associated with slower disease progression (HLA-A74:01, HLA-B44:03, HLA-B81:01, HLA-B57:03, HLA-DRB113). Fitness assays revealed that both women were infected with replication competent viruses, and both expressed higher mRNA levels of p21, a host restriction factor associated with viral control. HIV-specific T cell responses were examined using flow cytometry. EC1 mounted high frequency HIV-specific CD8+ T cell responses, including a B81:01-restricted Gag TL9 response. Unusually, EC2 had evidence of pre-infection HIV-specific CD4+ T cell responses.
We identified some features typical of elite controllers, including high magnitude HIV-specific responses and beneficial HLA. In addition, we made the atypical finding of pre-infection HIV-specific immunity in one elite controller, that may have contributed to very early viral control. This report highlights the importance of studying HIV controllers in high incidence settings.
大多数感染 HIV 的人需要接受抗逆转录病毒疗法 (ART) 来控制病毒复制,然而,也有极少数的 HIV 感染者能够自发且持久地控制病毒,而无需治疗。了解这些个体中是什么介导了病毒控制,使我们对可能有助于诱导 HIV 疫苗或功能性治愈的免疫机制有了深入的认识。迄今为止,在高发病率地区,仅有少数非洲精英控制者被描述过。我们从南非夸祖鲁-纳塔尔省的 CAPRISA 002 队列中确定了 HIV-1 亚型 C 感染的女性中的病毒学控制者,其中有 2 人(1%)是精英控制者。我们详细研究了这两名精英 HIV 控制者的遗传、临床、免疫和病毒学特征,以确定他们是否表现出与文献中描述的精英控制者相似的潜在病毒控制特征。
在本病例报告中,我们介绍了两名非洲女性在 HIV 感染 7 年期间的临床特征、CD4 T 细胞和病毒载量轨迹。在 Elite Controller 1(EC1)中,HIV 感染 10 个月后病毒载量不可检测,在 Elite Controller 2(EC2)中,6 周后病毒载量不可检测,并且在没有 ART 的情况下,在随访期间一直保持不可检测。两名精英控制者均表达了多种先前与疾病进展较慢相关的 HLA Ⅰ类和Ⅱ类单倍型(HLA-A74:01、HLA-B44:03、HLA-B81:01、HLA-B57:03、HLA-DRB113)。适应性测定显示,两名女性均感染了具有复制能力的病毒,并且均表达了更高水平的 p21 mRNA,这是一种与病毒控制相关的宿主限制因子。使用流式细胞术检测了 HIV 特异性 T 细胞反应。EC1 产生了高频率的 HIV 特异性 CD8+T 细胞反应,包括 B81:01 限制性 Gag TL9 反应。不寻常的是,EC2 有感染前 HIV 特异性 CD4+T 细胞反应的证据。
我们发现了一些典型的精英控制者特征,包括高幅度的 HIV 特异性反应和有益的 HLA。此外,我们还发现了一名精英控制者存在感染前 HIV 特异性免疫的异常发现,这可能有助于早期的病毒控制。本报告强调了在高发病率地区研究 HIV 控制者的重要性。